{'fraction_non_alphanumeric': 0.018633540372670808, 'fraction_numerical': 0.0037267080745341614, 'mean_word_length': 5.106060606060606, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery.

INTRODUCTION
The ability of most laboratories to easily access CRISPR/Cas9 engineering tools has caused a revolution in biology. One of the areas that will continue to be impacted by genome editing is the drug discovery process.


OBJECTIVE
CRISPR/Cas9 will not only serve to accelerate the drug discovery pipeline, but also streamline line it by identifying high-value targets, facilitating the validation of drug: target interactions and mechanisms of action, and stimulating the development of phenotype-based high throughput screens as alternatives to target-based assays.


CONCLUSION
We review the literature and hurdles that have been overcome to develop the current generation of tools being used to enrich the drug discovery paradigm.